Literature DB >> 7972041

Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene.

I G Maroulakou1, M Anver, L Garrett, J E Green.   

Abstract

A transgenic mouse model for prostate and mammary cancer has been developed in mice containing a recombinant gene expressing the simian virus 40 early-region transforming sequences under the regulatory control of the rat prostatic steroid binding protein [C3(1)] gene. Male transgenic mice develop prostatic hyperplasia in early life that progresses to adenoma or adenocarcinoma in most animals surviving to longer than 7 months of age. Prostate cancer metastases to lung have been observed. Female animals from the same founder lines generally develop mammary hyperplasia by 3 months of age with subsequent development of mammary adenocarcinoma by 6 months of age in 100% of the animals. The development of tumors correlates with the expression of the transgene as determined by Northern blot and immunohistochemical analyses. The results of these experiments demonstrate that the C3(1) regulatory region used in these experiments is useful for targeting expression to the prostate and mammary gland. To our knowledge, this experimental system is the first reported transgenic mouse model for prostate cancer. These transgenic animals offer the opportunity to study hormone response elements in vivo and the multistage progression from normal tissue to carcinoma in the prostate and mammary glands.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7972041      PMCID: PMC45202          DOI: 10.1073/pnas.91.23.11236

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  30 in total

1.  Prostatic steroid-binding protein. Isolation and characterization of C3 genes.

Authors:  M G Parker; R White; H Hurst; M Needham; R Tilly
Journal:  J Biol Chem       Date:  1983-01-10       Impact factor: 5.157

2.  Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic action of oncogenes in vivo.

Authors:  E Sinn; W Muller; P Pattengale; I Tepler; R Wallace; P Leder
Journal:  Cell       Date:  1987-05-22       Impact factor: 41.582

3.  Transplantable metastasizing prostate adenocarcinomas in rats.

Authors:  M Pollard; P H Luckert
Journal:  J Natl Cancer Inst       Date:  1975-03       Impact factor: 13.506

4.  Analysis of changes in rat prostate carcinoma following hormone deprivation.

Authors:  W C Beckman; A L Jacokes; J L Camps; R L Cook; G P Siegal
Journal:  Am J Pathol       Date:  1987-09       Impact factor: 4.307

5.  Autochthonous prostate adenocarcinomas in Lobund-Wistar rats: a model system.

Authors:  M Pollard; P H Luckert
Journal:  Prostate       Date:  1987       Impact factor: 4.104

6.  Ha-ras oncogene expression directed by a milk protein gene promoter: tissue specificity, hormonal regulation, and tumor induction in transgenic mice.

Authors:  A C Andres; C A Schönenberger; B Groner; L Hennighausen; M LeMeur; P Gerlinger
Journal:  Proc Natl Acad Sci U S A       Date:  1987-03       Impact factor: 11.205

7.  Color modification of diaminobenzidine (DAB) precipitation by metallic ions and its application for double immunohistochemistry.

Authors:  S M Hsu; E Soban
Journal:  J Histochem Cytochem       Date:  1982-10       Impact factor: 2.479

8.  Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene.

Authors:  W J Muller; E Sinn; P K Pattengale; R Wallace; P Leder
Journal:  Cell       Date:  1988-07-01       Impact factor: 41.582

9.  Cadmium carcinogenesis in male Wistar [Crl:(WI)BR] rats: dose-response analysis of tumor induction in the prostate and testes and at the injection site.

Authors:  M P Waalkes; S Rehm; C W Riggs; R M Bare; D E Devor; L A Poirier; M L Wenk; J R Henneman; M S Balaschak
Journal:  Cancer Res       Date:  1988-08-15       Impact factor: 12.701

10.  Variation in tumor yield in the prostate and other target organs of the rat in response to varied dosage and duration of administration of 3,2'-dimethyl-4-aminobiphenyl.

Authors:  N Ito; T Shirai; Y Tagawa; A Nakamura; S Fukushima
Journal:  Cancer Res       Date:  1988-08-15       Impact factor: 12.701

View more
  129 in total

1.  JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia.

Authors:  Andrea Bonetto; Tufan Aydogdu; Xiaoling Jin; Zongxiu Zhang; Rui Zhan; Leopold Puzis; Leonidas G Koniaris; Teresa A Zimmers
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-06-05       Impact factor: 4.310

2.  Natural history of tumor growth and immune modulation in common spontaneous murine mammary tumor models.

Authors:  Ekram Gad; Lauren Rastetter; Meredith Slota; Marlese Koehnlein; Piper M Treuting; Yushe Dang; Sasha Stanton; Mary L Disis
Journal:  Breast Cancer Res Treat       Date:  2014-11-14       Impact factor: 4.872

Review 3.  Interrogating mouse mammary cancer models: insights from gene expression profiling.

Authors:  Antonio A Fargiano; Kartiki V Desai; Jeffrey E Green
Journal:  J Mammary Gland Biol Neoplasia       Date:  2003-07       Impact factor: 2.673

Review 4.  Simian virus 40 transformation, malignant mesothelioma and brain tumors.

Authors:  Fang Qi; Michele Carbone; Haining Yang; Giovanni Gaudino
Journal:  Expert Rev Respir Med       Date:  2011-10       Impact factor: 3.772

5.  Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy.

Authors:  Patrick J Roberts; John E Bisi; Jay C Strum; Austin J Combest; David B Darr; Jerry E Usary; William C Zamboni; Kwok-Kin Wong; Charles M Perou; Norman E Sharpless
Journal:  J Natl Cancer Inst       Date:  2012-02-01       Impact factor: 13.506

6.  Blood outgrowth endothelial cell-based systemic delivery of antiangiogenic gene therapy for solid tumors.

Authors:  V Bodempudi; J R Ohlfest; K Terai; E A Zamora; R I Vogel; K Gupta; R P Hebbel; A Z Dudek
Journal:  Cancer Gene Ther       Date:  2010-08-20       Impact factor: 5.987

7.  Prostatic intraepithelial neoplasia in genetically engineered mice.

Authors:  Jae-Hak Park; Judy E Walls; Jose J Galvez; Minjung Kim; Cory Abate-Shen; Michael M Shen; Robert D Cardiff
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

8.  Erythropoietin promotes breast tumorigenesis through tumor-initiating cell self-renewal.

Authors:  Bing Zhou; Jeffrey S Damrauer; Sean T Bailey; Tanja Hadzic; Youngtae Jeong; Kelly Clark; Cheng Fan; Laura Murphy; Cleo Y Lee; Melissa A Troester; C Ryan Miller; Jian Jin; David Darr; Charles M Perou; Ross L Levine; Maximilian Diehn; William Y Kim
Journal:  J Clin Invest       Date:  2014-01-02       Impact factor: 14.808

9.  Dose-dependent benefits of quercetin on tumorigenesis in the C3(1)/SV40Tag transgenic mouse model of breast cancer.

Authors:  Jl Steiner; Jm Davis; Jl McClellan; Rt Enos; Ja Carson; R Fayad; M Nagarkatti; Ps Nagarkatti; D Altomare; Ke Creek; Ea Murphy
Journal:  Cancer Biol Ther       Date:  2014       Impact factor: 4.742

10.  Successful chemoimmunotherapy against hepatocellular cancer in a novel murine model.

Authors:  Guangfu Li; Dai Liu; Timothy K Cooper; Eric T Kimchi; Xiaoqiang Qi; Diego M Avella; Ningfei Li; Qing X Yang; Mark Kester; C Bart Rountree; Jussuf T Kaifi; David J Cole; Don C Rockey; Todd D Schell; Kevin F Staveley-O'Carroll
Journal:  J Hepatol       Date:  2016-08-09       Impact factor: 25.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.